Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the target of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 211,000 shares, a decline of 42.8% from the March 15th total of 369,200 shares. Based on an average trading volume of 9,850,000 shares, the short-interest ratio is presently 0.0 days. Approximately 1.1% of the shares of the company are short sold.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Eterna Therapeutics stock. Geode Capital Management LLC increased its holdings in Eterna Therapeutics Inc. (NASDAQ:ERNA) by 1,159.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 257,310 shares of the company’s stock after buying an additional 236,875 shares during the period. Geode Capital Management LLC owned 4.76% of Eterna Therapeutics worth $76,000 as of its most recent SEC filing. 70.55% of the stock is owned by institutional investors.

Eterna Therapeutics Stock Down 8.2 %

Shares of NASDAQ:ERNA opened at $0.18 on Thursday. The company has a 50-day moving average price of $0.25 and a two-hundred day moving average price of $0.49. Eterna Therapeutics has a twelve month low of $0.15 and a twelve month high of $2.63. The firm has a market capitalization of $9.60 million, a PE ratio of -0.02 and a beta of 4.79.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.